Preferred Medicine Inc., a joint venture between Preferred Networks Inc. (PFN) and Mitsui & Co., Ltd. (Mitsui), announced today that a joint research on machine learning-based cancer detections with circulating microRNA (miRNA) profiles in the blood will be presented at the 2021 annual meeting of American Society of Clinical Oncology (ASCO), to be held on June 4 - 8, 2021. The joint research was conducted in the U.S. by Preferred Networks America, Inc., Preferred Medicine and National Cancer Center Japan.
In the joint research, blood samples from patients with breast, colorectal, lung, stomach and pancreatic cancers, and non-cancer volunteers were collected through National Cancer Center Japan and other medical institutions. The entire miRNA expression profile was obtained with a next-generation sequencer and used to train machine learning models for cancer detection. The results will be presented at the ASCO poster session in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track on June 4, 2021.
The abstract has been published at:
The presented poster can also be downloaded at:
Liquid biopsy has received increasing attention as a promising method for non-invasive cancer detection. In particular, circulating miRNAs are seen as potential biomarkers that serve as a tool for detecting many types of cancer in early stages.
Originally published on June 3, 2021
About Preferred Medicine
Preferred Medicine, Inc. is a science-driven U.S. joint venture between Preferred Networks America, Inc. and Mitsui & Co., Ltd. The company was formed in November 2018 with the goal to commercialize biomedical and healthcare solutions using machine learning and deep learning technologies. Preferred Medicine is currently developing a non-invasive liquid biopsy product focused on women with a high risk for breast cancer.
Preferred Medicine is headquartered in Burlingame, California.
Preferred Medicine Inc. : Info@preferred-medicine.com
Sign up to be the first to hear any updates